William Collins > Goodwin > Boston, United States > Lawyer Profile
Goodwin Offices
100 NORTHERN AVENUE
BOSTON MA 02210
MASSACHUSETTS
United States
- Firm Profile
- Go to...
William Collins
Position
Partner
Career
William Collins is a partner in Goodwin’s nationally recognized Life Sciences group, counseling clients in the industries of biotechnology, pharmaceuticals and medical devices. Serving as his clients’ principal outside counsel, William provides strategic advice and corporate legal counseling to management teams and boards while structuring and leading significant transactions on his clients’ behalf. He is recognized by his clients and colleagues for his extensive industry knowledge and deal experience, and for providing practical legal and business advice. William has also been recognized as one of Law360’s Rising Stars for 2022.
William has extensive experience with startup and formation matters, venture capital financings, initial public offerings, deSPAC transactions and other equity debt capital markets transactions, mergers and acquisitions, strategic collaborations, and other complex transactions. He also represents a number of publicly traded biotechnology companies in ongoing SEC compliance, capital raising and corporate governance matters.
William has advised many of his clients through their full corporate life cycle, starting with their initial founding and funding. He also regularly represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments, exits and secondary stock sale transactions.
Education
JD, 2009, Boston University School of Law (cum laude) / BS, 2006, The University of Texas at Dallas (cum laude)
Lawyer Rankings
United States > M&A/corporate and commercial > Venture capital and emerging companies
(Leading partners)Goodwin’s signature technology expertise is a big draw for start-ups, while it also leverages a dominant life sciences offering that ‘provides everything a biotech company could need’. Alongside its company-side credentials, the group maintains close links with investors and it routinely advises venture capital funds on fundraisings, investments, and exits. From Boston, Mitch Bloom steers the life science practice and specializes in advising public and private life sciences companies and investors on financings, M&A, and public offerings. The technology and emerging companies team is co-led by Boston-based duo John Egan and Kenneth Gordon, together with Silicon Valley’s Craig Schmitz , all of whom act for an array of start-ups, growth companies, and investors. Other contacts in Boston include Bill Schnoor
, who, as previous head of the London office, is recommended for cross-border transactions involving the technology and life sciences sectors; Danielle Lauzon, who is recognized for her cutting-edge expertise in the life sciences field; and William Collins, who excels in matters involving the biotechnology, pharmaceuticals, and medical devices spheres. In Silicon Valley, Caine Moss focuses on supporting software, AI, internet, and financial services companies through all stages of their growth.
Lawyer Rankings
- Leading partners United States > M&A/corporate and commercial > Venture capital and emerging companies
- Venture capital and emerging companies United States > M&A/corporate and commercial
Top Tier Firm Rankings
- Industry focus > Cannabis
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Dispute resolution > E-discovery
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- Intellectual property > Patents: litigation (full coverage)
- Real estate > Real estate
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- M&A/corporate and commercial > Shareholder activism
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Capital markets: debt offerings
- International trade and national security > CFIUS
- Finance > Commercial lending
- M&A/corporate and commercial > Corporate governance
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- International trade and national security > Customs, export controls and economic sanctions
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Intellectual property > Patents: litigation (International Trade Commission)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Healthcare > Service providers
- Antitrust > Civil litigation/class actions: defense
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Real estate > Real estate finance
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Finance > Financial services regulation